Editas Medicine, Inc. (EDIT)

NMS – Real Time Price. Currency in USD

2.93

-0.13 (-4.25%)

At close: May 12, 2026, 4:00 PM EDT

2.92

-0.01 (-0.22%)

After-hours: May 12, 2026, 7:15 PM EDT

06.05.2026

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.

05.05.2026

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.43 per share a year ago.

05.05.2026

Editas Medicine Announces First Quarter 2026 Results and Business Updates

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates.

27.04.2026

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia.

13.04.2026

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

08.04.2026

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

27.03.2026

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).

Videos

No Data

There is no data to display

Press releases

05.05.2026

Editas Medicine Announces First Quarter 2026 Results and Business Updates

27.03.2026

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

09.03.2026

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates.

19.01.2026

Genflow Biosciences PLC Announces Directorate Change

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

Editas Medicine, Inc. (EDIT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Editas Medicine, Inc. (EDIT)

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Videos

No Data

Press releases

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Videos

No Data

Press releases

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change

Search stocks

Editas Medicine, Inc. (EDIT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Editas Medicine, Inc. (EDIT)

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Videos

No Data

Press releases

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Videos

No Data

Press releases

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change